A new survey commissioned by One A Day®, the multivitamin and supplement brand by Bayer rooted in more than 80 years of nutritional science, suggests ...
Authenticated data presented in the Chronic Kidney Disease market report is based on findings of extensive primary and secondary research ...
The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...
The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a ...
These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...
As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...
Zacks.com on MSN5d
Regeneron Reports Eylea Sales, Provides Other Pipeline UpdatesRegeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback